David A. Siegel Acer Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.13 - $4.15 $1,468 - $5,395	-1,300 Reduced 11.11%	10,400 $26,000
Q3 2022 Nov 14, 2022	SELL	$1.28 - $1.6 $256 - $320	-200 Reduced 1.68%	11,700 $16,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $3.04 $14,161 - $36,176	11,900 New	11,900 $15,000
Q3 2021 Nov 15, 2021	SELL	$2.3 - $2.86 $55,199 - $68,640	-24,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.52 - $3.18 $4,284 - $5,406	1,700 Added 7.62%	24,000 $69,000
Q1 2021 May 17, 2021	BUY	$2.47 - $4.39 $1,235 - $2,195	500 Added 2.29%	22,300 $69,000
Q4 2020 Feb 16, 2021	SELL	$2.34 - $2.99 $9,828 - $12,558	-4,200 Reduced 16.15%	21,800 $57,000
Q3 2020 Nov 16, 2020	BUY	$2.16 - $5.41 $25,056 - $62,756	11,600 Added 80.56%	26,000 $75,000
Q2 2020 Aug 14, 2020	SELL	$1.53 - $4.53 $1,377 - $4,077	-900 Reduced 5.88%	14,400 $49,000
Q1 2020 May 15, 2020	SELL	$1.18 - $5.86 $2,360 - $11,720	-2,000 Reduced 11.56%	15,300 $30,000
Q4 2019 Feb 14, 2020	BUY	$2.85 - $4.2 $2,850 - $4,200	1,000 Added 6.13%	17,300 $69,000
Q3 2019 Nov 14, 2019	BUY	$1.95 - $3.93 $31,785 - $64,059	16,300 New	16,300 $52,000

365

Ticker ACER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,100,000
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.